| Expression pattern: |
DN |
| Associated gene: |
PLAC8, KLF6, FOS |
| Associated microRNA: |
hsa-miR-181b-5p, hsa-miR-181d-5p, hsa-miR-2116-5p, hsa-miR-3119, hsa-miR-4423-3p, hsa-miR-4709-3p, hsa-miR-4752, hsa-miR-503-5p, hsa-miR-892b |
| Biological function: |
May participate in the pathogenesis/progression of HCC and serves as a stable serum biomarker; associated genes are enriched in hormone pathway and cell-cell interaction processes. |
| Molecular mechanism: |
Predicted ceRNA network (circRNA-miRNA-mRNA); circRNA1002 may sponge multiple miRNAs and regulate downstream mRNAs (predicted), with pathway enrichment including oxytocin signaling pathway and GO hormone secretion/transport and cell-cell adhesion terms. |
| Biological pathway or process: |
ceRNA regulation (other); other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Sanger Sequencing; Bioinformatics Analysis; Clinical Sample Validation |
| Clinical significance: |
circRNA1002 may be a reliable serum biomarker for HCC / early detection of HCC. |
| Description: |
circRNA1002 is consistently down-regulated in HBV-related HCC in both serum/whole blood and tumor tissue versus controls. The study proposes circRNA1002 as a stable serum biomarker for HCC and predicts a circRNA-miRNA-mRNA network involving multiple miRNAs and downstream mRNAs, with enrichment in hormone-related and cell-cell interaction processes. |
| Confidence score: |
0.5135 |